[Treatment of clinically localized prostate cancer. Part II--efficiency comparison of therapy methods].
The optimal management of clinically localized (T1, T2) prostate cancer remains controversial. In response to these controversies the American Urological Association guidelines considered surgery, radiotherapy or watchful waiting to be options, because the literature does not provide clear evidence for the superiority of any one treatment. The aim of this paper is presentation of current knowledge regarding this problem.
Szelachowska
Jolanta
J
Medical University of Wroclaw, Poland.
Kornafel
Jan
J
Gisterek
Iwona
I
D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects; D002277:Carcinoma / Q000188:drug therapy / Q000453:epidemiology / Q000532:radiotherapy* / Q000601:surgery*; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D008875:Middle Aged; D011467:Prostate; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy / Q000009:adverse effects* / Q000706:statistics & numerical data; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000453:epidemiology / Q000532:radiotherapy* / Q000601:surgery*; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D016019:Survival Analysis; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D017430:Prostate-Specific Antigen